AbbVie Inc.
confirmed Tuesday a deal to buy pharmaceutical company Allergan PLC AGN, -0.95% in a deal with equity value of $63 billion. Allergan's stock soared 30% in premarket trading while AbbVie shares tumbled 9.9%. Under terms of the deal, Allergan shareholders will receive 0.8660 and $120.30 in cash for each Allergan share they own, which based on Monday closing prices values Allergan shares at $188.24 each, a 45.3% premium. Based on 327.
Source: News Formal (newsformal.com)
Overpaid?
Wow
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Abbvie is buying Allergan in a $63 billion pharma mega-dealThe biopharmaceuticals giant and drugmaker are combining to create a leader across immunology, neuroscience, eye care and other medical fields.
Source: BusinessInsider - 🏆 729. / 51 Read more »
AbbVie Nears Deal to Buy Allergan for More Than $60 BillionAbbVie is nearing a deal to buy Allergan for more than $60 billion, as the two big drug makers bet a combination will deliver new sources of growth they have struggled to find on their own. TrueBubbleHead just looked at $AGN. This may change the Trade of the Week Legal cartels. Growth meaning price gouging.
Source: WSJ - 🏆 98. / 63 Read more »
AbbVie Nears Deal to Buy Allergan for More Than $60 BillionAbbVie is nearing a deal to buy Allergan for more than $60 billion, as the two big drug makers bet a combination will deliver new sources of growth they have struggled to find on their own. TrueBubbleHead just looked at $AGN. This may change the Trade of the Week Legal cartels. Growth meaning price gouging.
Source: WSJ - 🏆 98. / 63 Read more »
Abbvie is buying Allergan in a $63 billion pharma mega-dealThe biopharmaceuticals giant and drugmaker are combining to create a leader across immunology, neuroscience, eye care and other medical fields.
Source: BusinessInsider - 🏆 729. / 51 Read more »
Caesars' stock soars after Eldorado buyout deal values casino operator at about $8.6 billionShares of Caesars Entertainment Corp. soared 16% toward an 11-month high in premarket trading Monday, after the casino operator agreed to be bought out by... how the hell can the 'El Dorado' afford to buy the much bigger more successful Caesar's...doesn't make sense...
Source: MarketWatch - 🏆 3. / 97 Read more »
Circor rejects Crane's buyout deal valued at $1.7 billionCircor International Inc. said Monday it has rejected the unsolicited buyout bid from Crane Co. given that it 'substantially undervalues' the flow...
Source: MarketWatch - 🏆 3. / 97 Read more »